Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) [[An]] A phenyl or heteroaryl amino alkane derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



(I)

wherein

Ar represents phenylene or a 5 or 6 membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of O, N and S,

wherein

said ~~phenyl~~ phenylene or [[a]] 5 or 6 membered heteroaryl optionally ~~having~~ has one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino, formyl, (C_{1-6})alkylthio, (C_{1-6})alkoxy and (C_{1-6})alkyl optionally substituted by hydroxy, or mono-, di- or tri- halogen;

Q^1, Q^2, $Q^3$and Q^4 independently represent CH, CR^{10} or N;

wherein

R^{10} represents halogen, cyano, amino, nitro, formyl, hydroxymethyl, methylthio, (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, or (C_{1-6})alkoxy optionally substituted by phenyl;

R^1 represents $-OR^{11}$, $-CH_2NHR^{11}$, $-C(O)R^{11}$, $-C(O)NHR^{11}$, $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-NHR^{11}$, $-NHC(O)OR^{11}$, $-NHC(O)NR^{11}$, $-NHC(O)R^{11}$, $-NHSO_2R^{11}$, hydrogen, hydroxy, or halogen, or

a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N, or

(C_{1-6})alkyl optionally substituted by aryloxyimino, (C_{1-6})alkoxy optionally substituted by aryl or heteroaryl, or

[[or]] a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N, or

(C_{2-6})alkenyl optionally substituted by a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N, or

(C_{2-6})alkynyl optionally substituted by a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N,

in any of which the saturated or unsaturated 3-10 membered mono- or bi-cyclic ring may be optionally substituted by one or more substituents selected from the group consisting of

halogen, hydroxy, cyano, nitro, (C_{1-6}) alkylthio,

(C_{1-6})alkyl optionally substituted by mono-, di-, or tri- halogen,

(C_{1-6})alkoxy optionally substituted by mono-, di-, or tri- halogen,

aryl optionally substituted by nitro, (C_{1-6})alkyl or (C_{1-6})alkoxy,

aralkyl optionally, at the aryl moiety, substituted by nitro, (C_{1-6})alkyl or (C_{1-6})alkoxy,

and

aryloxy optionally substituted by nitro, (C_{1-6})alkyl or (C_{1-6})alkoxy,

wherein

R^{11} represents (C_{1-6})alkoxy(C_{1-6})alkylene,

a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N,

(C_{1-6})alkyl optionally substituted by mono-, di- or tri-halogen or a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N,

(C_{2-6})alkenyl optionally substituted by a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N, or

(C_{2-6})alkynyl optionally substituted by a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N,

in any of which the saturated or unsaturated 3-10 membered mono- or bi-cyclic ring may be optionally substituted by one or more substituents selected from the group consisting of

halogen, hydroxy, cyano, nitro,

(C_{1-6})alkoxy optionally substituted by mono-, di-, or tri- halogen, and

(C_{1-6})alkyl optionally substituted by mono-, di-, or tri- halogen;

R^2 represents hydrogen, hydroxy, amino, N-(C_{1-6})alkylamino, (C_{2-6})alkenyl, (C_{2-6})alkynyl, (C_{3-7})cycloalkyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulfonyl, aryl, heteroaryl, or

(C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, (C_{1-6})alkylsulfonyl, (C_{1-6})alkylthio, aryl or heteroaryl, or

(C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen, (C_{1-6})alkylsulfonyl, aryl or heteroaryl,

in any of which the aryl or heteroaryl may optionally be substituted by one or more substituents selected from the group consisting of halogen, hydroxy, nitro, amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino, N-(4,5-dihydro-1H-imidazole)amino, (C_{1-6})alkyl, phenyl, a 5 or 6

membered heteroaryl containing 1 to 3 heteroatoms selected from the group of O, N, and S,

and

(C_{1-6})alkoxy optionally substituted by morpholino, amino, N-(C_{1-6})alkylamino, or N,N-di(C_{1-6}) alkylamino;

R^3 represents hydrogen or (C_{1-6})alkyl optionally substituted mono-, di- or tri-halogen;

R^4 represents carboxy, tetrazolyl or N-(hydroxy)aminocarbonyl;

R^5 represents hydrogen, (C_{1-6})alkoxy, aryl, heteroaryl or (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen;

R^6 represents hydrogen or (C_{1-6})alkyl optionally substituted by mono-, di- or tri-halogen; and

R^7 represents hydrogen, or (C_{1-6})alkyl.

2. (Currently amended) The phenyl or heteroaryl amino alkane derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

Ar represents



Q^5, Q^6, Q^7 and Q^8 independently represent CH, CR^8 or N,

Q^9, Q^{10} and Q^{12} independently represent O, S, CH, CR^8, CH_2, NH, or NR^9,

wherein

R^8 represents halogen, cyano, amino, nitro, formyl, hydroxymethyl, methylthio, (C_{1-6})alkoxy, or (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen,

R^9 represents (C_{1-6})alkyl;

Q^1, Q^2, $Q^3$and Q^4 independently represent CH, CR^{10} or N,

wherein

R^{10} represents halogen, amino, nitro, formyl, hydroxymethyl, methylthio, (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, or (C_{1-6})alkoxy optionally substituted by phenyl;

R^1 represents $-OR^{11}$, $-CH_2NHR^{11}$, $-C(O)R^{11}$, $-C(O)NHR^{11}$, $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-NHR^{11}$, $-NHC(O)R^{11}$, $-NHC(O)OR^{11}$, $-NHC(O)NR^{11}$, $-NHSO_2R^{11}$, hydrogen, hydroxy, halogen, <u>or</u>

a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] <u>and</u> N, <u>or</u>

(C_{1-6})alkyl optionally substituted by aryloxyimino, (C_{1-6})alkoxy optionally substituted by aryl or hereoaryl, or a saturated or unsaturated 3-10 membered

mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N, or

(C_{2-6})alkenyl optionally substituted by a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N, or

(C_{2-6})alkynyl optionally substituted by a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N,

in any of which the saturated or unsaturated 3-10 membered mono- or bi-cyclic ring may be optionally substituted by one or more substituents selected from the group consisting of

halogen, hydroxy, cyano, nitro, (C_{1-6})alkylthio,

(C_{1-6})alkyl optionally substituted by mono-, di-, or tri- halogen,

(C_{1-6})alkoxy optionally substituted by mono-, di-, or tri- halogen,

aryl optionally substituted by nitro, (C_{1-6})alkyl or (C_{1-6}) alkoxy,

aralkyl optionally, at the aryl moiety, substituted by nitro, (C_{1-6})alkyl or (C_{1-6})alkoxy,

and

aryloxy optionally substituted by nitro, (C_{1-6})alkyl or (C_{1-6})alkoxy,

wherein

R^{11} represents (C_{1-6})alkoxy(C_{1-6})alkylene,

a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N,

(C_{1-6})alkyl optionally substituted by mono-, di- or tri-halogen or a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N,

(C_{2-6})alkenyl optionally substituted by a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N, or

(C_{2-6})alkynyl optionally substituted by a saturated or unsaturated 3-10 membered mono- or bi-cyclic ring optionally having one or two heteroatoms selected independently from O [[or]] and N,

in any of which the saturated or unsaturated 3-10 membered mono- or bi-cyclic ring may be optionally substituted by one or more substituents selected from the group consisting of

halogen, hydroxy, cyano, nitro,

(C_{1-6})alkoxy optionally substituted by mono-, di-, or tri- halogen, and

(C_{1-6})alkyl optionally substituted by mono-, di-, or tri- halogen;

R^2 represents hydrogen, hydroxy, amino, N-(C_{1-6})alkylamino, (C_{2-6})alkenyl, (C_{2-6})alkynyl, (C_{3-7})cycloalkyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulfonyl, aryl, heteroaryl,

(C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, (C_{1-6})alkylsulfonyl, (C_{1-6})alkylthio, aryl or heteroaryl, or

(C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen, (C_{1-6})alkylsulfonyl, aryl or heteroaryl,

in any of which the aryl or heteroaryl may optionally be substituted by one or more substituents selected from the group consisting of halogen, hydroxy, nitro, amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino, N-(4,5-dihydro-1H-imidazole)-amino, (C_{1-6})alkyl, phenyl, a 5 or 6 membered heteroaryl containing 1 to 4 heteroatoms selected from the group of O, N, and S,

and

(C_{1-6})alkoxy optionally substituted by morpholino, amino, N-(C_{1-6})alkylamino, or N,N-di(C_{1-6}) alkylamino;

R^3 represents hydrogen, or C_{1-6} alkyl optionally substituted mono, di- or tri- halogen;

R^4 represents carboxy, tetrazolyl or N-(hydroxy)aminocarbonyl;

R^5 represents hydrogen, (C_{1-6})alkyl, (C_{1-6})alkoxy, aryl or heteroaryl;

R^6 represents hydrogen; and

R^7 represents hydrogen, or (C_{1-6})alkyl.

3. (Original) The phenyl or heteroaryl amino alkane derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

Ar represents



,

Q^5, Q^6, Q^7 and Q^8 independently represent CH, CR^8 or N,

wherein

R^8 represents halogen, cyano, amino, nitro, formyl, hydroxymethyl, methylthio, (C_{1-6})alkoxy, or (C_{1-6})alkyl optionally substituted by mono-, di-, or tri- halogen;

Q^1, Q^2, Q^3 and Q^4 independently represent CH, CR^{10} or N,

wherein

R^{10} represents halogen, amino, nitro, formyl, trifluoromethyl, hydroxymethyl, methylthio or benzyloxy;

R^1 represents $-OR^{11}$, $-CH_2OR^{11}$, $-CH_2NHR^{11}$, $-C(O)R^{11}$, $-C(O)NHR^{11}$, $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-NHR^{11}$, $-NHC(O)R^{11}$, $-NHC(O)OR^{11}$, $-NHC(O)NR^{11}$, $-NHSO_2R^{11}$, hydrogen, hydroxy, halogen,

(C_{1-6})alkyl optionally substituted by phenoxyimino, (C_{1-6})alkoxy or R^{12},

wherein

said (C_{1-6}) alkoxy optionally substituted by pyrrolyl, pyrazolyl, imidazolyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, or dihydroisoquinolyl,

(C_{2-6})alkenyl optionally substituted by R^{12},

(C_{2-6})alkynyl optionally substituted by R^{12}, or

one of the following carbocyclic or heterocyclic rings selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl pyrrolyl, piperidino, piperidyl, piperazinyl, pyrazolyl, imidazolyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, and dihydroisoquinolyl,

in any of which the carbocyclic or heterocyclic rings may optionally be substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, carboxy, amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino, (C_{1-6})alkylthio, phenyl, phenoxy, benzyl, naphthyl, (C_{1-6})alkyl optionally substituted by mono-,di- or tri- halogen, and (C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen, or phenyl;

wherein

R^{11} represents (C_{1-6})alkoxy (C_{1-6})alkylene,

(C_{1-6})alkyl optionally substituted by R^{101},

(C_{2-6})alkenyl optionally substituted by R^{101},

(C_{2-6})alkynyl optionally substituted by R^{101}, or

one of the following carbocyclic or heterocyclic rings selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl pyrrolyl, piperidino, piperidyl, piperazinyl, pyrazolyl, imidazolyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, and dihydroisoquinolyl,

in any of which the carbocyclic or heterocyclic rings may optionally be substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, carboxy, amino, N-$(C_{1-6}$alkyl)amino, N,N-di$(C_{1-6}$alkyl)amino, (C_{1-6})alkylthio, phenyl, phenoxy, benzyl, naphthyl, (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, and (C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen,

R^{101} represents one of the following carbocyclic or heterocyclic rings selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrrolyl, piperidino, piperidyl, piperazinyl, pyrazolyl, imidazolyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, and dihydroisoquinolyl,

in any of which the carbocyclic or heterocyclic rings may optionally be substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, carboxy, amino, N-$(C_{1-6}$alkyl)amino, N,N-di$(C_{1-6}$alkyl)amino, (C_{1-6})alkylthio, phenyl, phenoxy, benzyl, naphthyl, (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, and (C_{1-6})alkoxy optionally substituted by mono-, di-, or tri- halogen;

R^{12} represents one of the following carbocyclic or heterocyclic rings selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl pyrrolyl, piperidino, piperidyl, piperazinyl, pyrazolyl, imidazolyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, and dihydroisoquinolyl,

in any of which the carbocyclic or heterocyclic rings may optionally be substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, carboxy, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6}alkyl)amino, (C_{1-6})alkylthio, phenyl, phenoxy, benzyl, naphthyl, (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, and (C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen;

R^2 represents hydrogen, hydroxy, amino, N-(C_{1-6})alkylamino, (C_{2-6})alkenyl, (C_{2-6})alkynyl, (C_{3-7})cycloalkyl, pyrimidinyl, indolyl, pyridyl,

(C_{1-6})alkoxy optionally substituted by amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino, or phenyl,

(C_{1-6})alkyl optionally substituted by phenyl, mono-, di- or tri- halogen, (C_{1-6})alkylthio, or (C_{1-6})alkylsulfonyl,

phenyl optionally substituted by halogen, hydroxy, nitro, amino, N-(C_{1-6})alkylamino, N-(dihydroimidazolyl)amino, (C_{1-6})alkyl, or (C_{1-6})alkoxy optionally substituted by R^{21},

wherein

R^{21} represents amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino, or morpholino;

R^3 represents hydrogen, or (C_{1-6})alkyl optionally substituted by mono-, di- or tri-halogen;

R^4 represents carboxy, tetrazolyl or N-(hydroxy)aminocarbonyl;

R^5 represents hydrogen, (C_{1-6})alkyl, (C_{1-6})alkoxy, phenyl, pyridyl, pyrazinyl, pyrimidinyl, or pyridazinyl;

R^6 represents hydrogen; and

R^7 represents hydrogen or (C_{1-6})alkyl.

4. (Currently amended) The phenyl or heteroaryl amino alkane derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

Ar represents



,

Q^5 and Q^7 independently represent CH or N,

Q^6 and Q^8 independently represent CH or CR^8,

wherein

R^8 represents halogen, cyano, amino, nitro, formyl, hydroxymethyl, methylthio or trifluoromethyl;

Q^1 independently represent represents CH or CR^{10},

wherein

R^{10} represents halogen, cyano, amino, nitro, formyl, trifluoromethyl, hydroxymethyl, methylthio or benzyloxy;

Q^2, Q^3 and Q^4 represent CH;

R^1 represents $-OR^{11}$, $-CH_2NHR^{11}$, $-C(O)R^{11}$, $-C(O)NHR^{11}$, $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-NHR^{11}$, $-NHC(O)R^{11}$, $-NHC(O)OR^{11}$, $-NHC(O)NR^{11}$, $-NHSO_2R^{11}$, hydrogen, hydroxy, halogen,

(C_{1-6})alkyl optionally substituted by (C_{1-6})alkoxy or R^{12},

wherein

said (C_{1-6}) alkoxy optionally substituted by pyrrolyl, pyrazolyl, imidazolyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, or dihydroisoquinolyl,

(C_{2-6})alkenyl optionally substituted by R^{12},

(C_{2-6})alkynyl optionally substituted by R^{12}, or

one of the following carbocyclic or heterocyclic rings selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl

pyrrolyl, piperidino, piperidyl, piperazinyl, pyrazolyl, imidazolyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, and dihydroisoquinolyl,

in any of which the carbocyclic or heterocyclic rings may optionally be substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6}alkyl)amino, (C_{1-6})alkylthio, phenyl, phenoxy, benzyl, naphthyl,

(C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, and

(C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen,

wherein

R^{11} represents (C_{1-6})alkoxy(C_{1-6})alkylene,

(C_{1-6})alkyl optionally substituted by R^{101},

(C_{2-6})alkenyl optionally substituted by R^{101},

(C_{2-6})alkynyl optionally substituted by R^{101}, or

one of the following carbocyclic or heterocyclic rings selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl pyrrolyl, piperidino, piperidyl, piperazinyl, pyrazolyl, imidazolyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, and dihydroisoquinolyl,

in any of which the carbocyclic or heterocyclic rings may optionally be substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino, (C_{1-6})alkylthio, phenyl, phenoxy, benzyl, naphthyl, (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, and (C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen,

R^{101} represents one of the following carbocyclic or heterocyclic rings selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl pyrrolyl, phenyl, pyridyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, and dihydroisoquinolyl,

in any of which the carbocyclic or heterocyclic rings may optionally be substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6}alkyl)amino, (C_{1-6})alkylthio, phenyl, phenoxy, benzyl, naphthyl, (C_{1-6})alkyl optionally substituted by mono-, di- or tri-halogen, and (C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen;

R^{12} represents one of the following carbocyclic or heterocyclic rings selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl pyrrolyl, phenyl, pyridyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, and dihydroisoquinolyl,

in any of which the carbocyclic or heterocyclic rings may optionally be substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, amino, N-(C_{1-6})alkylamino,

N,N-di(C_{1-6})alkylamino, (C_{1-6})alkylthio, phenyl, phenoxy, benzyl, naphthyl, (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, and (C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen;

R^2 represents hydrogen, hydroxy, (C_{2-6})alkenyl, (C_{2-6})alkynyl, (C_{3-7})cycloalkyl, pyrimidinyl, indolyl, pyridyl,

(C_{1-6})alkoxy optionally substituted by amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino or phenyl,

(C_{1-6})alkyl optionally substituted by phenyl, mono-, di- or tri- halogen, (C_{1-6}) alkylthio or (C_{1-6})alkylsulfonyl,

phenyl optionally substituted by halogen, hydroxy, nitro, amino, N-(C_{1-6})alkylamino, N-(dihydroimidazolyl)amino, (C_{1-6})alkyl, or (C_{1-6})alkoxy optionally substituted by R^{21}

wherein

R^{21} represents amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino or morpholino;

R^3 represents hydrogen or (C_{1-6})alkyl optionally substituted by mono-, di- or tri-halogen;

R^4 represents carboxy, tetrazolyl or N-(hydroxy)aminocarbonyl;

R^5 represents hydrogen, (C_{1-6})alkyl, (C_{1-6})alkoxy, phenyl or pyridinyl;

R^6 represents hydrogen; and

R^7 represents hydrogen, methyl or ethyl.

5. (Original) The phenyl or heteroaryl amino alkane derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

Ar represents



,

Q^5 and Q^7 represent N;

Q^6 and Q^8 independently represent CH or CR^8,

wherein

R^8 represents fluoro, chloro, amino, nitro, formyl, hydroxymethyl, trifluoromethyl, or methylthio;

Q^1, Q^2, $Q^3$and Q^4 represent CH or CR^{10},

wherein

R^{10} represents halogen, amino, nitro, formyl, trifluoromethyl, hydroxymethyl, methylthio or benzyloxy;

R^1 represents $-OR^{11}$, $-CH_2NHR^{11}$, $-C(O)R^{11}$, $-C(O)NHR^{11}$, $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-NHR^{11}$, $-NHC(O)R^{11}$, $-NHC(O)OR^{11}$, $-NHC(O)NR^{11}$, $-NHSO_2R^{11}$, hydrogen, hydroxy, halogen, benzodioxolyl, naphthyl,

phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of nitro, (C_{1-6})alkoxy, (C_{1-6})alkylthio, phenyl, and phenoxy,

(C_{1-6}) alkyl optionally substituted by anilino, N-(benzyl)amino, indolyl, isoindolyl, quinolyl, isoquinolyl, dihydroisoquinolyl, phenoxyimino, phenyl optionally substituted by halogen, or (C_{1-6}) alkoxy,

wherein

said (C_{1-6}) alkoxy optionally substituted by phenyl, pyridyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, isoquinolyl, or dihydroisoquinolyl,

(C_{2-6})alkenyl optionally substituted by phenyl,

(C_{2-6})alkynyl optionally substituted by phenyl,

wherein

R^{11} represents (C_{1-6})alkoxy(C_{1-6})alkylene,

(C_{1-6}) alkyl optionally substituted by R^{101},

(C_{2-6})alkenyl optionally substituted by R^{101},

(C_{2-6})alkynyl optionally substituted by R^{101}, or

one of the following carbocyclic or heterocyclic rings selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl pyrrolyl, phenyl, pyridyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, and dihydroisoquinolyl,

in any of which the carbocyclic or heterocyclic rings may optionally be substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, (C_{1-6})alkylthio, phenyl, phenoxy, benzyl, naphthyl, (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, or (C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen,

R^{101} represents one of the following carbocyclic or heterocyclic rings selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl pyrrolyl, phenyl, pyridyl, pyrimidinyl, benzodioxolyl, naphthyl, indolyl, isoindolyl, quinolyl, and dihydroisoquinolyl,

in any of which the carbocyclic or heterocyclic rings may optionally be substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, (C_{1-6})alkylthio, phenyl, phenoxy, benzyl, naphthyl, (C_{1-6})alkyl optionally substituted by mono-, di- or tri- halogen, and (C_{1-6})alkoxy optionally substituted by mono-, di- or tri- halogen,

R^2 represents hydrogen, hydroxy, (C_{2-6})alkenyl, (C_{2-6})alkynyl, pyrimidinyl, indolyl, pyridyl,

(C_{1-6})alkoxy optionally substituted by phenyl,

(C_{1-6})alkyl optionally substituted by phenyl, methylthio, mono-, di- or tri- halogen, or (C_{1-6}) alkylsulfonyl,

phenyl optionally substituted by halogen, hydroxy, nitro, amino, N-(dihydroimidazolyl)amino or (C_{1-6})alkoxy,

wherein

said (C_{1-6})alkoxy optionally substituted by amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino, or morpholino;

R^3 represents hydrogen or (C_{1-6})alkyl;

R^4 represents carboxy, tetrazolyl or N-(hydroxy)aminocarbonyl;

R^5 represents hydrogen, phenyl or pyridyl;

R^6 represents hydrogen; and

R^7 represents hydrogen.

6. (Original) The phenyl or heteroaryl amino alkane derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

Ar represents



;

Q^1, Q^2, Q^3 and Q^4 represent CH;

R^1 represents hydrogen, hydroxy, halogen, benzodioxolyl, naphthyl, cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, cyclopentylcarbonyl, cyclohexylcarbonyl, pyrrolidinylmethoxy, pyrrolidinylethoxy, phenoxy, benzyloxy, fluorobenzyloxy, difluorobenzyloxy, hydroxybenzyloxy, methoxybenzyloxy, dimethoxybenzyloxy, 1H-pyrrolylmethoxy, 1H-pyrrolylethoxy, pyridinyloxy, trifluorometylpyridinyloxy, pyridinylmethoxy, phenylethoxy, pyridinylethoxy, phenylpropoxy, cyanopyridinyloxy, pyrimidinyloxy, trifluoromethylpyrimidinyloxy, quinolinyloxy, benzoyl, fluorobenzoyl, chlorobenzoyl, anilinocarbonyl, benzylamino, benzoylamino, phenylacetylamino, phenylsulfonylamino, fuluoro phenylsulfonylamino, cyclopropylmethylamino, anilinomethyl,

phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of nitro, methoxy, ethoxy, methylthio, phenyl, and phenoxy,

(C_{1-6})alkyl optionally substituted by anilino, N-(benzyl)amino, indolyl, isoindolyl, quinolyl, isoquinolyl, dihydroisoquinolyl, phenoxy, phenoxyimino, or phenyl optionally substituted by halogen,

(C_{2-6})alkenyl optionally substituted by phenyl,

(C_{2-6})alkynyl optionally substituted by phenyl, or

(C_{1-6})alkoxy optionally substituted by trifluoro or methoxy;

R^2 represents hydrogen, (C_{2-6})alkenyl, (C_{2-6})alkynyl, pyrimidinyl, indolyl, pyridyl,

(C_{1-6})alkoxy optionally substituted by phenyl,

(C_{1-6})alkyl optionally substituted by phenyl, methylthio, mono-, di- or tri- halogen, or (C_{1-6})alkylsulfonyl,

phenyl optionally substituted by halogen, hydroxy, nitro, amino, N-(dihydroimidazolyl)amino or (C_{1-6})alkoxy optionally substituted by amino, N-(C_{1-6})alkylamino, N,N-di(C_{1-6})alkylamino, or morpholino;

R^3 represents hydrogen;

R^4 represents carboxy or tetrazolyl;

R^5 represents hydrogen;

R^6 represents hydrogen; and

R^7 represents hydrogen.

7. (Currently amended) The phenyl or heteroaryl amino alkane derivative, its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said derivative is selected from the group consisting of the following compounds:

3-(2-aminoethoxy)-N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}phenylalanine;
4-chloro-N-{6-[4-(cyclopropylmethoxy)phenyl]pyrimidin-4-yl}phenylalanine;
N-(6-{4-[(2-fluorobenzyl)oxy]phenyl}pyrimidin-4-yl)phenylalanine;
N-(6-{4-[(3,5-difluorobenzyl)oxy]phenyl}pyrimidin-4-yl)-3-pyridin-2-ylalanine;
N-(6-{4-[(3,5-difluorobenzyl)oxy]phenyl}pyrimidin-4-yl)norleucine;
N-(6-{4-[(3,5-difluorobenzyl)oxy]phenyl}pyrimidin-4-yl)phenylalanine;
N-(6-{4-[(3,5-dimethoxybenzyl)oxy]phenyl}pyrimidin-4-yl)-3-pyridin-2-ylalanine;
N-(6-{4-[(3,5-dimethoxybenzyl)oxy]phenyl}pyrimidin-4-yl)norleucine;

N-(6-{4-[(3,5-dimethoxybenzyl)oxy]phenyl}pyrimidin-4-yl)phenylalanine;

N-(6-{4-[(3-fluorobenzyl)oxy]phenyl}pyrimidin-4-yl)-3-pyridin-2-ylalanine;

N-(6-{4-[(3-fluorobenzyl)oxy]phenyl}pyrimidin-4-yl)phenylalanine;

N-(6-{4-[(3-methoxybenzyl)oxy]phenyl}pyrimidin-4-yl)-3-pyridin-2-ylalanine;

N-(6-{4-[(3-methoxybenzyl)oxy]phenyl}pyrimidin-4-yl)norleucine;

N-(6-{4-[(3-methoxybenzyl)oxy]phenyl}pyrimidin-4-yl)phenylalanine;

N-(6-{4-[(4-fluorobenzyl)oxy]phenyl}pyrimidin-4-yl)phenylalanine;

N-(6-{4-[2-(1H-pyrrol-1-yl)ethoxy]phenyl}pyrimidin-4-yl)phenylalanine;

N-[6-(3'-methoxybiphenyl-4-yl)pyrimidin-4-yl]phenylalanine;

N-[6-(4'-methoxybiphenyl-4-yl)pyrimidin-4-yl]phenylalanine;

N-{6-[4-(1,3-benzodioxol-5-yl)phenyl]pyrimidin-4-yl}phenylalanine;

N-{6-[4-(2-phenylethoxy)phenyl]pyrimidin-4-yl}-3-pyridin-2-ylalanine;

N-{6-[4-(2-phenylethoxy)phenyl]pyrimidin-4-yl}phenylalanine;

N-{6-[4-(benzyloxy)-3-fluorophenyl]pyrimidin-4-yl}-3-pyridin-2-ylalanine;

N-{6-[4-(benzyloxy)-3-fluorophenyl]pyrimidin-4-yl}phenylalanine;

N-{6-[4-(benzyloxy)phenyl]-5-fluoropyrimidin-4-yl}phenylalanine;

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-3-(2-morpholin-4-ylethoxy)phenylalanine;

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-3-[2-(dimethylamino)ethoxy]phenylalanine;

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-3-hydroxyphenylalanine;

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-3-pyridin-2-yl-alanine;

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-4-chlorophenylalanine;

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-4-fluorophenylalanine;

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-norleucine;

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-phenylalanine;

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}tryptophan;

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}tyrosine;

N-{6-[4-(cyclopropylmethoxy)phenyl]pyrimidin-4-yl}-4-fluorophenylalanine;

N-{6-[4-(cyclopropylmethoxy)phenyl]pyrimidin-4-yl}-phenylalanine;

N-{6-[4-(phenoxymethyl)phenyl]pyrimidin-4-yl}phenylalanine;

N-{6-[4-(phenylethynyl)phenyl]pyrimidin-4-yl}phenylalanine;

N-{6-[4-(pyridin-3-ylmethoxy)phenyl]pyrimidin-4-yl}phenylalanine; and

N-{6-[6-(benzyloxy)pyridin-3-yl]pyrimidin-4-yl}phenylalanine[[;]] .

8. (Original) The phenyl or heteroaryl amino alkane derivative, its tautomeric or a salt thereof as claimed in claim 1, wherein said derivative is selected from the group consisting of the following compounds:

N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-3-pyridin-2-yl-D-alanine;
N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-D-norleucine;
N-{6-[4-(benzyloxy)phenyl]pyrimidin-4-yl}-D-phenylalanine; and
N-{6-[4-(cyclopropylmethoxy)phenyl]pyrimidin-4-yl}-D-phenylalanine.

9. (Currently amended) A ~~medicament~~ pharmaceutical composition comprising the phenyl or heteroaryl amino alkane derivative, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient , and a pharmaceutically acceptable carrier.

10. (Cancelled)

11. (Currently amended) The ~~medicament~~ pharmaceutical composition as claimed in claim 9, wherein the phenyl or heteroaryl amino alkane derivative, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is an IP receptor antagonist.

12. (Currently amended) ~~The medicament as claimed in claim 9 for prophylaxis and/or treatment of urological disorder or disease~~ A method for prophylaxis and/or treatment of a urological disorder comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

13. (Currently amended) ~~The medicament as claimed in claim 9 for prophylaxis and/or treatment of pain~~ A method for prophylaxis and/or treatment of pain comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

14. (Currently amended) ~~The medicament as claimed in claim 9 for prophylaxis and/or treatment of hypotension~~ A method for prophylaxis and/or treatment of hypertension comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

15. (Currently amended) ~~The medicament as claimed in claim 9 for prophylaxis and/or treatment of hemophilia and hemorrhage~~ A method for prophylaxis and/or treatment of hemophilia and hemorrhage comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

16. (Currently amended) ~~The medicament as claimed in claim 9 for prophylaxis and/or treatment of inflammation~~ A method for prophylaxis and/or treatment of inflammation comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Currently amended) ~~Process~~ A method for controlling a urological ~~disorders~~ disorder in ~~humans and animals~~ a human or animal ~~by~~ comprising administration of an IP receptor-~~antagonisticly~~antagonistically effective amount of at least one compound according to ~~claims~~ claim 1.